(19E,21E,23E,25E,27E,29E,31E)-33-(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (19E,21E,23E,25E,27E,29E,31E)-33-(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid
• 化学式: C₄₇H₇₃NO₁₇
• 分子量: 924.1
• InChiKey: APKFDSVGJQXUKY-QVDADOJXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  65
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.66
• 拓扑面积：
  320
• 氢给体数：
  12
• 氢受体数：
  18

文献信息

• POLYENE MACROLIDE DERIVATIVE
  申请人：SHIONOGI & CO., LTD.

  公开号：EP3156410A1

  公开（公告）日：2017-04-19

  The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.

  本发明是以下两性霉素 B 衍生物： 其中各符号在说明中定义。本发明化合物的第 16 位（X）是脲结构、环状结构、羟烷基或取代的单烷基氨基甲酰基。本发明化合物具有抗真菌活性。
• Polyene macrolide derivative
  申请人：Shionogi & Co., Ltd.

  公开号：US10246478B2

  公开（公告）日：2019-04-02

  The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.

  本发明是以下两性霉素 B 衍生物： 其中各符号在说明中定义。本发明化合物的第 16 位（X）是脲结构、环状结构、羟烷基或取代的单烷基氨基甲酰基。本发明化合物具有抗真菌活性。
• METHODS AND FORMULATIONS FOR REDUCING AMPHOTERICIN B TREATMENT SIDE EFFECTS
  申请人：Cleary John D.

  公开号：US20110152211A1

  公开（公告）日：2011-06-23

  A method of ameliorating amphotericin treatment side effects in a mammal that comprises administering a therapeutically effective amount of a formulation that comprises a polyene active ingredient that includes amphotericin B, wherein the amphotericin B compound is present, in terms of polyene content, in an amount greater than 90%, and non-amphotericin B polyene compounds are present in an amount of no greater than 10%, and a pharmaceutically effective carrier; and administering a therapeutically effective amount of said formulation to a subject in need thereof.
• ANTIFUNGAL AND ANTIPARASITIC POLYENE MACROLIDES
  申请人：ACEA Biotech, Inc.

  公开号：US20160129026A1

  公开（公告）日：2016-05-12

  In certain aspects, the present disclosure provides for novel, water-soluble polyene macrolides and salts or solvates thereof and methods of making the water-soluble polyene macrolides. Also provided are compositions and methods for inhibiting, preventing, and/or treating fungal and parasitic diseases in a subject.
• US7867981B2
  申请人：——

  公开号：US7867981B2

  公开（公告）日：2011-01-11